Drugmakers that complain about the growing cost to bring new molecular entities to market aren't exaggerating, according to a study released Tuesday by the Tufts Center for the Study of Drug Development (CSDD). Read More
Ever since Gilead Sciences Inc. unveiled its $84,000 price tag for Solvaldi, a breakthrough hepatitis C drug, many lawmakers, patient groups and payers have been throwing warning flags about the escalating price of drugs. Read More
As analysts congratulated Neostem Inc. on phase II data with its autologous stem cell therapy for acute myocardial infarction (AMI) and the "incredibly pleased" company hailed the results as "exciting," Wall Street bludgeoned the shares (NASDAQ:NBS), which ended Tuesday at $4.78, down $2, or 29.5 percent. Read More
HONG KONG - Researchers from the Riken Institute in Japan have discovered a mechanism through which the enteric Enterobacteriaceae bacteria can adjust to the very different oxygen environments within and outside of the human gut, an important finding that could represent a new drug target and ultimately lead to the development of new antimicrobials. Read More
Intellia Therapeutics Inc., a new company formed to develop CRISPR-Cas9 therapeutics for gene editing and repair, closed a $15 million series A round led by Atlas Venture and Novartis Institutes for Biomedical Research. Read More
NEW DELHI – India has eased the process of patent applications for pharmaceutical companies by dropping a mandatory clause put in place to check whether claims of new discoveries attached to patent applications are valid – meaning that they are actually new discoveries. Read More
LONDON – After a barnstorming year for public biotechs across all segments of market capitalization, the sector as a whole is entering a new age of maturity. Read More
SHANGHAI – For a small start-up with only two and a half years under its belt, Suzhou Connect Biopharmaceuticals Inc., of Suzhou, Jiangsu, is understandably pleased to be kicking off its phase I trials for CBP-307 in Australia. Read More
Myos Corp., of Cedar Knolls, N.J., entered an agreement with selected institutional investors to raise about $1.81 million in gross proceeds in a registered direct offering through the sale of 193,865 shares of its common stock at a price of $9.37 per share. Read More
Allied-Bristol Life Sciences LLC, of Boston, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb Co., of New York, formed a strategic partnership with Synergy Partners R&D Solutions LLC, a network of scientists offering expertise in areas such as disease biology, medicinal chemistry, process chemistry, toxicology, pharmacology and drug safety. Read More
Forward Pharma A/S, of Copenhagen, said it filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd., units of Cambridge, Mass.-based Biogen Idec Inc., in the Regional Court in Dusseldorf, alleging infringement of its German utility model DE 20 2005 022 112 due to Biogen Idec's marketing of multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) in Germany. Read More
Capricor Therapeutics Inc., of Los Angeles, presented one-year results from the phase II ALLSTAR (Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration) trial at the American Heart Association's Annual Scientific Sessions 2014 in Chicago. Read More
Novartis AG, of Basel, Switzerland, said data on its investigational compound, LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF) showed the compound has the potential to change the course of the disease. Read More
